Aegirbio AB
STO:AEGIR
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| SE |
A
|
Aegirbio AB
STO:AEGIR
|
6.9m SEK |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
403.4B USD |
Loading...
|
|
| US |
|
Astria Therapeutics Inc
NASDAQ:ATXS
|
326.4B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
205.6B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
182.9B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
123.9B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81.4B USD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.3B EUR |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
70.2B AUD |
Loading...
|
Market Distribution
| Min | -5 565 412.8% |
| 30th Percentile | -5.3% |
| Median | 3% |
| 70th Percentile | 7.5% |
| Max | 12 228% |
Other Profitability Ratios
Aegirbio AB
Glance View
AegirBio AB engages in the development and commercialization of drug monitoring tests. The company is headquartered in Lund, Skane. The company went IPO on 2020-06-26. The firm offers tests to monitor and optimize the dosage of biological drugs via its patented technology platform. The company aims to provide personalized treatment by tracking drugs levels in individuals. Aegirbio combines core technologies from LifeAssays and Abreos Biosciences. LifeAssays is a diagnostics company based in Sweden, which owns the Magnia Point of Care and Point of Need reader technology. Abreos Biosciences is a California-based biotech, which is a developer of the Veritope chemistry platform for detecting levels of biologic drugs in patient samples.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Aegirbio AB is -137 155.6%, which is above its 3-year median of -153 544.7%.
Over the last 3 years, Aegirbio AB’s Net Margin has decreased from -133 850% to -137 155.6%. During this period, it reached a low of -370 709.1% on Sep 30, 2023 and a high of -670.7% on Sep 30, 2021.
